Oxford BioDynamics PLC OBD presents latest EpiSwitch data at ASH Summit
July 17 2018 - 1:00AM
RNS Non-Regulatory
TIDMOBD
Oxford BioDynamics PLC
17 July 2018
17 July 2018
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
OBD presents latest data on the use of EpiSwitch(TM) in
predicting patient response to immunotherapy and identifying
lymphoma subtypes
-- EpiSwitch(TM) biomarkers have the potential to predict
patient response to treatments with immune checkpoint inhibitors
anti-PD-1 and anti-PD-L1
-- EpiSwitch(TM) biomarkers have been shown to offer prognostic
stratifications in lymphoma patients
-- Data presented at the ASH Summit on Emerging Immunotherapies
for Hematologic Diseases on 13 July 2018, in Washington DC
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company
focused on the discovery and development of epigenetic biomarkers
based on regulatory genome architecture, for use within the
pharmaceutical and biotechnology industry, has presented its latest
EpiSwitch(TM) data in a plenary talk at the American Society of
Hematology (ASH) Summit on Emerging Immunotherapies for Hematologic
Diseases, 12-13 July 2018, Washington DC, entitled: "Chromosome
Conformation Monitoring for Prognostic Stratifications of
Non-responders to Cancer Immunotherapies: Deconvolution of
Epigenetic data with EpiSwitch(TM)."
Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford
BioDynamics, presented data on prognostic blood-based
stratifications of patients with a common type of Non-Hodgkin
lymphoma, and on predictive biomarkers for response to treatment
with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1. Data
presented from several indications successfully demonstrated that
EpiSwitch(TM) epigenetic biomarkers identified in patients' blood
could help identify patients that will not respond adequately to
anti-PD-1 or anti-PD-L1 monotherapy. Based on further analysis of
more than 126 patients, this validation study demonstrated 94%
accuracy in predicting response to the anti-PD-L1 treatment.
Immunotherapy, particularly immune checkpoint inhibitor
PD-1/PD-L1 treatments, is a type of therapy that harnesses a
person's immune system to fight cancer cells. Lymphomas represent a
broad range of blood cancers based on diseases of white cells.
While Hodgkin lymphomas show good response to immunotherapies,
response and efficacy in other lymphomas remain modest at best. OBD
is actively involved in the fast moving field of immunotherapy,
with a number of proprietary and commercial studies based on immune
checkpoint inhibitors, monotherapies and combination therapies, for
a growing list of cancer types.
Through the development of epigenetic biomarkers, OBD's
EpiSwitch(TM) technology can help pharmaceutical and biotechnology
companies bring drugs to the market sooner through personalising
drugs to patients most likely to respond, delivering better
clinical outcomes.
Dr Alexandre Akoulitchev, Chief Scientific Officer of Oxford
BioDynamics, commented:
"There have been many exciting breakthroughs in the
immunotherapy of cancerous and non-cancerous hematologic diseases,
including immune checkpoint inhibitors. However, questions of
safety and efficacy present significant challenges, with a high
demand for molecular biomarkers that may help to predict clinical
outcomes.
Our aim is to develop and deliver non-invasive prognostic
biomarkers in this fast developing and competitive field, and we
were pleased to present strong data at this ASH Summit. Our
EpiSwitch(TM) technology could stratify and predict which patients
would not respond adequately to checkpoint inhibitor therapy, with
high accuracy. We are very pleased with the interest our data have
generated amongst the leaders in the field.
We believe that successful epigenetic stratifications of
patients using EpiSwitch(TM) biomarkers could help improve
understanding of the regulatory mechanisms in blood disorders, gain
valuable insights into new targets and treatment designs, as well
as help improve patients outcomes by supporting clinical decisions
on the most appropriate and effective treatment option."
-ENDS-
For further details contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar, CEO
Paul Stockdale, CFO
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations
Advisor
Brett Pollard
Natalie Garland-Collins
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABLGDRGUBBGIL
(END) Dow Jones Newswires
July 17, 2018 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024